Aurora Pujol

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6991803/aurora-pujol-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

135 papers	10,743 citations	42 h-index	103 g-index
144 ext. papers	13,797 ext. citations	9.4 avg, IF	5.17 L-index

#	Paper	IF	Citations
135	Human genetic and immunological determinants of critical COVID-19 pneumonia.. *Nature*, **2022**,	50.4	23
134	Diagnosis of Genetic White Matter Disorders by Singleton Whole-Exome and Genome Sequencing Using Interactome-Driven Prioritization.. *Neurology*, **2022**,	6.5	2
133	Low Lymphocytes and IFN-Neutralizing Autoantibodies as Biomarkers of COVID-19 Mortality.. *Journal of Clinical Immunology*, **2022**, 1	5.7	0
132	Studying severe long COVID to understand post-infectious disorders beyond COVID-19.. *Nature Medicine*, **2022**,	50.5	6
131	Accelerated biological aging in COVID-19 patients.. *Nature Communications*, **2022**, 13, 2135	17.4	4
130	Systematic Collaborative Reanalysis of Genomic Data Improves Diagnostic Yield in Neurologic Rare Diseases.. *Journal of Molecular Diagnostics*, **2022**, 24, 529-542	5.1	1
129	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2200413119	11.5	3
128	A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection. *Nature Immunology*, **2021**,	19.1	7
127	Bi-allelic variants in the mitochondrial RNase P subunit PRORP cause mitochondrial tRNA processing defects and pleiotropic multisystem presentations. *American Journal of Human Genetics*, **2021**, 108, 2195-2204	11	3
126	Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. *EBioMedicine*, **2021**, 65, 103246	8.8	25
125	Epigenome-wide association study of COVID-19 severity with respiratory failure. *EBioMedicine*, **2021**, 66, 103339	8.8	33
124	SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease?. *Journal of Experimental Medicine*, **2021**, 218,	16.6	45
123	Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain. *Journal of Clinical Immunology*, **2021**, 41, 914-922	5.7	35
122	Loss of function mutations in GEMIN5 cause a neurodevelopmental disorder. *Nature Communications*, **2021**, 12, 2558	17.4	4
121	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model. *Neuropathology and Applied Neurobiology*, **2021**,	5.2	2
120	CSVS, a crowdsourcing database of the Spanish population genetic variability. *Nucleic Acids Research*, **2021**, 49, D1130-D1137	20.1	8
119	Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment. *Neuropathology and Applied Neurobiology*, **2021**, 47, 544-563	5.2	7

118	DLG4-related synaptopathy: a new rare brain disorder. *Genetics in Medicine*, **2021**, 23, 888-899	8.1	0
117	From Your Nose to Your Toes: A Review of Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic-Associated Pernio. *Journal of Investigative Dermatology*, **2021**, 141, 2791-2796	4.3	6
116	Biallelic PI4KA variants cause a novel neurodevelopmental syndrome with hypomyelinating leukodystrophy. *Brain*, **2021**, 144, 2659-2669	11.2	2
115	Autoantibodies neutralizing type I IFNs are present in 4% of uninfected individuals over 70 years old and account for 20% of COVID-19 deaths. *Science Immunology*, **2021**, 6,	28	91
114	X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. *Science Immunology*, **2021**, 6,	28	67
113	A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. *Cell*, **2020**, 181, 1194-1199	56.2	113
112	High-dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy. *Brain Pathology*, **2020**, 30, 945-963	6	4
111	Improved Diagnosis of Rare Disease Patients through Systematic Detection of Runs of Homozygosity. *Journal of Molecular Diagnostics*, **2020**, 22, 1205-1215	5.1	8
110	POLR3A variants with striatal involvement and extrapyramidal movement disorder. *Neurogenetics*, **2020**, 21, 121-133	3	13
109	The peroxisomal fatty acid transporter ABCD1/PMP-4 is required in the C. elegans hypodermis for axonal maintenance: A worm model for adrenoleukodystrophy. *Free Radical Biology and Medicine*, **2020**, 152, 797-809	7.8	9
108	HNRNPH1-related syndromic intellectual disability: Seven additional cases suggestive of a distinct syndromic neurodevelopmental syndrome. *Clinical Genetics*, **2020**, 98, 91-98	4	9
107	Phenotypic correlations in a large single-center cohort of patients with BSCL2 nerve disorders: a clinical, neurophysiological and muscle magnetic resonance imaging study. *European Journal of Neurology*, **2020**, 27, 1364-1373	6	0
106	Truncating variants in UBAP1 associated with childhood-onset nonsyndromic hereditary spastic paraplegia. *Human Mutation*, **2020**, 41, 632-640	4.7	8
105	A deep intronic splice variant advises reexamination of presumably dominant SPG7 Cases. *Annals of Clinical and Translational Neurology*, **2020**, 7, 105-111	5.3	13
104	The Value of Mouse Models of Rare Diseases: A Spanish Experience. *Frontiers in Genetics*, **2020**, 11, 583932	4.5	6
103	Impairment of the mitochondrial one-carbon metabolism enzyme SHMT2 causes a novel brain and heart developmental syndrome. *Acta Neuropathologica*, **2020**, 140, 971-975	14.3	11
102	Ceramide signalling in inherited and multifactorial brain metabolic diseases. *Neurobiology of Disease*, **2020**, 143, 105014	7.5	7
101	A novel hypomorphic splice variant in EIF2B5 gene is associated with mild ovarioleukodystrophy. *Annals of Clinical and Translational Neurology*, **2020**, 7, 1574-1579	5.3	2

100	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science*, **2020**, 370,	33.3	994
99	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science*, **2020**, 370,	33.3	1090
98	Case Report: Benign Infantile Seizures Temporally Associated With COVID-19. *Frontiers in Pediatrics* , **2020**, 8, 507	3.4	14
97	Expanding the clinical and genetic spectrum of PCYT2-related disorders. *Brain*, **2020**, 143, e76	11.2	7
96	Complete loss of KCNA1 activity causes neonatal epileptic encephalopathy and dyskinesia. *Journal of Medical Genetics*, **2020**, 57, 132-137	5.8	16
95	Clinical presentation and proteomic signature of patients with TANGO2 mutations. *Journal of Inherited Metabolic Disease*, **2020**, 43, 297-308	5.4	17
94	Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study. *Neurotherapeutics*, **2019**, 16, 1167-1182	6.4	19
93	A novel mutation in the gene expands the phenotype of Alexander disease. *Journal of Medical Genetics*, **2019**, 56, 846-849	5.8	4
92	FAHN/SPG35: a narrow phenotypic spectrum across disease classifications. *Brain*, **2019**, 142, 1561-1572	11.2	34
91	Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism. *Movement Disorders*, **2019**, 34, 1547-1561	7	26
90	Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy. *Journal of Clinical Investigation*, **2019**, 129, 1240-1256	15.9	37
89	Reply to: "Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion". *Movement Disorders*, **2019**, 34, 1932-1933	7	
88	Epigenomic signature of adrenoleukodystrophy predicts compromised oligodendrocyte differentiation. *Brain Pathology*, **2018**, 28, 902-919	6	15
87	Evaluation of afferent pain pathways in adrenomyeloneuropathic patients. *Clinical Neurophysiology*, **2018**, 129, 507-515	4.3	3
86	Dual Molecular Effects of Dominant RORA Mutations Cause Two Variants of Syndromic Intellectual Disability with Either Autism or Cerebellar Ataxia. *American Journal of Human Genetics*, **2018**, 102, 744-759	11	30
85	Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 712-721	6.1	20
84	Oxidative stress and mitochondrial dynamics malfunction are linked in Pelizaeus-Merzbacher disease. *Brain Pathology*, **2018**, 28, 611-630	6	9
83	Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy. *EMBO Molecular Medicine*, **2018**, 10,	12	26

82	Inhibition of Gsk3b Reduces Nfkb1 Signaling and Rescues Synaptic Activity to Improve the Rett Syndrome Phenotype in Mecp2-Knockout Mice. *Cell Reports*, **2018**, 23, 1665-1677	10.6	20
81	SIRT2 in age-related neurodegenerative disorders. *Aging*, **2018**, 10, 295-296	5.6	5
80	Mutations in Histone Acetylase Modifier BRPF1 Cause an Autosomal-Dominant Form of Intellectual Disability with Associated Ptosis. *American Journal of Human Genetics*, **2017**, 100, 105-116	11	26
79	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy. *Acta Neuropathologica*, **2017**, 133, 283-301	14.3	31
78	De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause Intellectual Disability. *American Journal of Human Genetics*, **2017**, 101, 768-788	11	81
77	Loss of SIRT2 leads to axonal degeneration and locomotor disability associated with redox and energy imbalance. *Aging Cell*, **2017**, 16, 1404-1413	9.9	27
76	Allelic Expression Imbalance Promoting a Mutant PEX6 Allele Causes Zellweger Spectrum Disorder. *American Journal of Human Genetics*, **2017**, 101, 965-976	11	31
75	De novo loss of function mutations in KIAA2022 are associated with epilepsy and neurodevelopmental delay in females. *Clinical Genetics*, **2017**, 91, 756-763	4	13
74	A view on clinical genetics and genomics in Spain: of challenges and opportunities. *Molecular Genetics & Genomic Medicine*, **2016**, 4, 376-91	2.3	3
73	Uniparental disomy of chromosome 16 unmasks recessive mutations of FA2H/SPG35 in 4 families. *Neurology*, **2016**, 87, 186-91	6.5	21
72	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
71	Novel Therapeutic Targets and Drug Candidates for Modifying Disease Progression in Adrenoleukodystrophy. *Endocrine Development*, **2016**, 30, 147-60		9
70	Targeted activation of CREB in reactive astrocytes is neuroprotective in focal acute cortical injury. *Glia*, **2016**, 64, 853-74	9	21
69	Oxidative stress, mitochondrial and proteostasis malfunction in adrenoleukodystrophy: A paradigm for axonal degeneration. *Free Radical Biology and Medicine*, **2015**, 88, 18-29	7.8	39
68	Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species. *Journal of Neuropathology and Experimental Neurology*, **2015**, 74, 319-44	3.1	86
67	Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy. *Cell Death and Differentiation*, **2015**, 22, 1742-53	12.7	23
66	Altered glycolipid and glycerophospholipid signaling drive inflammatory cascades in adrenomyeloneuropathy. *Human Molecular Genetics*, **2015**, 24, 6861-76	5.6	25
65	Deregulation of purine metabolism in Alzheimer© disease. *Neurobiology of Aging*, **2015**, 36, 68-80	5.6	78

64	Mitochondrial Disease Sequence Data Resource (MSeqDR): a global grass-roots consortium to facilitate deposition, curation, annotation, and integrated analysis of genomic data for the mitochondrial disease clinical and research communities. *Molecular Genetics and Metabolism*, **2015**, 114, 388-96	3.7	56
63	Autophagy induction halts axonal degeneration in a mouse model of X-adrenoleukodystrophy. *Acta Neuropathologica*, **2015**, 129, 399-415	14.3	31
62	Astrocytes and mitochondria from adrenoleukodystrophy protein (ABCD1)-deficient mice reveal that the adrenoleukodystrophy-associated very long-chain fatty acids target several cellular energy-dependent functions. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2015**, 1852, 925-36	6.9	36
61	Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. *Cell Metabolism*, **2014**, 19, 1034-41	24.6	175
60	PGC-1 overexpression exacerbates amyloid and tau deposition in a transgenic mouse model of Alzheimer disease. *FASEB Journal*, **2014**, 28, 1745-55	0.9	41
59	Improvement of the Rett syndrome phenotype in a MeCP2 mouse model upon treatment with levodopa and a dopa-decarboxylase inhibitor. *Neuropsychopharmacology*, **2014**, 39, 2846-56	8.7	17
58	Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. *Human Molecular Genetics*, **2014**, 23, 3716-32	5.6	96
57	Mitochondrial dysfunction and oxidative damage cooperatively fuel axonal degeneration in X-linked adrenoleukodystrophy. *Biochimie*, **2014**, 98, 143-9	4.6	36
56	Mitochondrial dysfunction in central nervous system white matter disorders. *Glia*, **2014**, 62, 1878-94	9	43
55	PDR-1/hParkin negatively regulates the phagocytosis of apoptotic cell corpses in Caenorhabditis elegans. *Cell Death and Disease*, **2014**, 5, e1120	9.8	12
54	ABCD2 alters peroxisome proliferator-activated receptor signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesity. *Molecular Pharmacology*, **2014**, 86, 505-13	4.3	5
53	Glutathione imbalance in patients with X-linked adrenoleukodystrophy. *Molecular Genetics and Metabolism*, **2013**, 109, 366-70	3.7	34
52	Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. *Human Molecular Genetics*, **2013**, 22, 3296-305	5.6	83
51	Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. *Brain*, **2013**, 136, 2432-43	11.2	57
50	Oxidative stress regulates the ubiquitin-proteasome system and immunoproteasome functioning in a mouse model of X-adrenoleukodystrophy. *Brain*, **2013**, 136, 891-904	11.2	32
49	Cyclophilin D as a potential target for antioxidants in neurodegeneration: the X-ALD case. *Biological Chemistry*, **2013**, 394, 621-9	4.5	4
48	Functional genomics reveals dysregulation of cortical olfactory receptors in Parkinson disease: novel putative chemoreceptors in the human brain. *Journal of Neuropathology and Experimental Neurology*, **2013**, 72, 524-39	3.1	83
47	Histone deacetylase inhibitor upregulates peroxisomal fatty acid oxidation and inhibits apoptotic cell death in abcd1-deficient glial cells. *PLoS ONE*, **2013**, 8, e70712	3.7	14

46	Neurochemistry and the non-motor aspects of PD. *Neurobiology of Disease*, **2012**, 46, 508-26	7.5	66
45	Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer© disease. *Brain Pathology*, **2012**, 22, 636-53	6	71
44	Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation. *Journal of Inherited Metabolic Disease*, **2012**, 35, 1137-45	5.4	33
43	Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases?. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2012**, 1822, 1475-88	6.9	71
42	ATP and noradrenaline activate CREB in astrocytes via noncanonical Ca(2+) and cyclic AMP independent pathways. *Glia*, **2012**, 60, 1330-44	9	12
41	Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. *Human Molecular Genetics*, **2012**, 21, 5091-105	5.6	47
40	Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy. *Brain*, **2012**, 135, 3584-98	11.2	62
39	Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy. *Human Molecular Genetics*, **2012**, 21, 1062-77	5.6	55
38	The absence of ABCD2 sensitizes mice to disruptions in lipid metabolism by dietary erucic acid. *Journal of Lipid Research*, **2012**, 53, 1071-9	6.3	15
37	JNK/ERK/FAK mediate promigratory actions of basic fibroblast growth factor in astrocytes via CCL2 and COX2. *NeuroSignals*, **2012**, 20, 86-102	1.9	13
36	Phylogenomic evidence for a myxococcal contribution to the mitochondrial fatty acid beta-oxidation. *PLoS ONE*, **2011**, 6, e21989	3.7	5
35	The ABCD Subfamily: Peroxisomal Transporters in Health and Disease **2011**, 347-373		
34	Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. *Annals of Neurology*, **2011**, 70, 84-92	9.4	107
33	Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy. *Antioxidants and Redox Signaling*, **2011**, 15, 2095-107	8.4	68
32	Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. *Brain Pathology*, **2010**, 20, 845-56	6	75
31	Staging anti-inflammatory therapy in Alzheimer© disease. *Frontiers in Aging Neuroscience*, **2010**, 2, 142	5.3	27
30	Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. *Human Molecular Genetics*, **2010**, 19, 2005-14	5.6	77
29	ABCD2 is abundant in adipose tissue and opposes the accumulation of dietary erucic acid (C22:1) in fat. *Journal of Lipid Research*, **2010**, 51, 162-8	6.3	28

28	PeroxisomeDB 2.0: an integrative view of the global peroxisomal metabolome. *Nucleic Acids Research*, **2010**, 38, D800-5	20.1	81
27	General aspects and neuropathology of X-linked adrenoleukodystrophy. *Brain Pathology*, **2010**, 20, 817-30	6	92
26	Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis. *Brain Pathology*, **2010**, 20, 838-44	6	94
25	Schilder© disease a heterogenous group of disorders known as X-linked adrenoleukodystrophy. Foreword. *Brain Pathology*, **2010**, 20, 815-6	6	3
24	Invariant NKT cells in adrenoleukodystrophy patients and mice. *Journal of Neuroimmunology*, **2010**, 229, 204-11	3.5	6
23	A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. *American Journal of Physiology - Endocrinology and Metabolism*, **2009**, 296, E211-21	6	72
22	Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adrenoleukodystrophy mouse model. *Annals of Neurology*, **2009**, 66, 117-22	9.4	25
21	Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. *Human Molecular Genetics*, **2008**, 17, 1762-73	5.6	158
20	Steroid hormones control circadian Elovl3 expression in mouse liver. *Endocrinology*, **2008**, 149, 3158-66	4.8	39
19	The role of peroxisomal ABC transporters in the mouse adrenal gland: the loss of Abcd2 (ALDR), Not Abcd1 (ALD), causes oxidative damage. *Laboratory Investigation*, **2007**, 87, 261-72	5.9	32
18	PeroxisomeDB: a database for the peroxisomal proteome, functional genomics and disease. *Nucleic Acids Research*, **2007**, 35, D815-22	20.1	63
17	The evolutionary origin of peroxisomes: an ER-peroxisome connection. *Molecular Biology and Evolution*, **2006**, 23, 838-45	8.3	138
16	Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. *Human Molecular Genetics*, **2005**, 14, 3565-77	5.6	81
15	Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. *Human Molecular Genetics*, **2004**, 13, 2997-3006	5.6	149
14	Mouse liver PMP70 and ALDP: homomeric interactions prevail in vivo. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2004**, 1689, 235-43	6.9	45
13	Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. *Human Molecular Genetics*, **2002**, 11, 499-505	5.6	151
12	ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. *Human Mutation*, **2001**, 18, 499-515	4.7	210
11	Inhibition of transcription-regulating properties of nonstructural protein 1 (NS1) of parvovirus minute virus of mice by a dominant-negative mutant form of NS1. *Journal of General Virology*, **2001**, 82, 1929-1934	4.9	4

10	Characterization of the adrenoleukodystrophy-related (ALDR, ABCD2) gene promoter: inductibility by retinoic acid and forskolin. *Genomics*, **2000**, 70, 131-9	4.3	23
9	Activation of promoter P4 of the autonomous parvovirus minute virus of mice at early S phase is required for productive infection. *Journal of Virology*, **1999**, 73, 3877-85	6.6	49
8	The nucleotide sequence of Saccharomyces cerevisiae chromosome XV. *Nature*, **1997**, 387, 98-102	50.4	51
7	Sequence and analysis of a 36.2 kb fragment from the right arm of yeast chromosome XV reveals 19 open reading frames including SNF2 (5Œend), CPA1, SLY41, a putative transport ATPase, a putative ribosomal protein and an SNF2 homologue. *Yeast*, **1997**, 13, 479-82	3.4	3
6	Inhibition of parvovirus minute virus of mice replication by a peptide involved in the oligomerization of nonstructural protein NS1. *Journal of Virology*, **1997**, 71, 7393-403	6.6	37
5	Complete nucleotide sequence of Saccharomyces cerevisiae chromosome X.. *EMBO Journal*, **1996**, 15, 2031-2049	13	65
4	Sequencing analysis of a 40□2 kb fragment of yeast chromosome X reveals 19 open reading frames including URA2 (5? end), TRK1, PBS2, SPT10, GCD14, RPE1, PHO86, NCA3, ASF1, CCT7, GZF3, two tRNA genes, three remnant delta elements and a Ty4 transposon. *Yeast*, **1996**, 12, 1471-1474	3.4	6
3	Isolation of a fully infectious variant of parvovirus H-1 supplanting the standard strain in human cells. *Journal of Virology*, **1995**, 69, 4538-43	6.6	40
2	Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in males		1
1	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males		2